착상전 유전자 검사 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global preimplantation genetic testing market size is expected to reach USD 2587.76 Million in 2034 from USD 1021.51 Million in 2025, growing at a CAGR of 10.88% during 2026-2034.The global preimplantation genetic testing market is growing rapidly as assisted reproductive technologies become more advanced and widely adopted. Preimplantation genetic testing (PGT) is used during in vitro fertilization (IVF) to screen embryos for genetic abnormalities before implantation. This process helps improve the chances of a successful pregnancy and reduces the risk of genetic disorders.

A major driver of the market is the increasing prevalence of genetic diseases and infertility issues among couples worldwide. As awareness of genetic screening increases, more patients are opting for advanced reproductive technologies. Additionally, improvements in genomic sequencing and genetic analysis technologies have made PGT more accurate and reliable.

Looking ahead, the preimplantation genetic testing market is expected to expand significantly as reproductive medicine continues to advance. The growing demand for personalized reproductive healthcare and improved IVF success rates will support market growth. Ongoing research in genetics and reproductive biology will likely create new opportunities for advanced embryo screening technologies.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

• Chromosomal Abnormalities
• Aneuploidy
• X-Linked Diseases
• Single Gene Disorders
• Hla Typing
• Gender Selection
• Others

By End User

• Diagnostic Laboratories
• Hospitals
• Clinics
• Others

COMPANIES PROFILED

• CooperSurgical, Illumina, Natera, Vitrolife, Igenomix, Fulgent Genetics, Eurofins Scientific, Genomic Prediction, Reproductive Genetics Institute, Natera/Parental Embryo Screening, Juno Genetics, Igenomix/Vitrolife, GenEmbryomics, CooperGenomics, EvolveGene, Juno Genomics, LifeView, Genesis Genetics, Progenesis, Reprogenetics

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Chromosomal Abnormalities Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Aneuploidy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. X-Linked Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Single Gene Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Hla Typing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Gender Selection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET: BY END USER 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast End User
• 5.2. Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PREIMPLANTATION GENETIC TESTING MARKET: BY REGION 2022-2034 (USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Type
  • 6.2.2 By End User
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Type
  • 6.3.2 By End User
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Spain
  • 6.3.8 Russia
  • 6.3.9 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Type
  • 6.4.2 By End User
  • 6.4.3 China
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 India
  • 6.4.7 Australia
  • 6.4.8 South East Asia
  • 6.4.9 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Type
  • 6.5.2 By End User
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Type
  • 6.6.2 By End User
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL PREIMPLANTATION GENETIC TESTING INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 CooperSurgical
  • 8.2.2 Illumina
  • 8.2.3 Natera
  • 8.2.4 Vitrolife
  • 8.2.5 Igenomix
  • 8.2.6 Fulgent Genetics
  • 8.2.7 Eurofins Scientific
  • 8.2.8 Genomic Prediction
  • 8.2.9 Reproductive Genetics Institute
  • 8.2.10 Natera/Parental Embryo Screening
  • 8.2.11 Juno Genetics
  • 8.2.12 Igenomix/Vitrolife
  • 8.2.13 GenEmbryomics
  • 8.2.14 CooperGenomics
  • 8.2.15 EvolveGene
  • 8.2.16 Juno Genomics
  • 8.2.17 LifeView
  • 8.2.18 Genesis Genetics
  • 8.2.19 Progenesis
  • 8.2.20 Reprogenetics